| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 02/16/2023 | — | JMP Securities | Downgrades | Market Outperform → Market Perform | |
| 10/07/2022 | -80.45% | Cantor Fitzgerald | $2.5 → $0.17 | Downgrades | Overweight → Neutral |
| 11/29/2021 | 72.49% | JMP Securities | → $1.5 | Initiates Coverage On | → Outperform |
| 01/22/2021 | 244.99% | Cantor Fitzgerald | → $3 | Initiates Coverage On | → Overweight |
| 01/21/2021 | 244.99% | Cantor Fitzgerald | → $3 | Initiates Coverage On | → Overweight |
| 06/26/2020 | 216.24% | Alliance Global Partners | → $2.75 | Initiates Coverage On | → Buy |
What is the target price for iBio (IBIO)?
The latest price target for iBio (AMEX: IBIO) was reported by JMP Securities on February 16, 2023. The analyst firm set a price target for $0.00 expecting IBIO to fall to within 12 months (a possible -100.00% downside). 2 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for iBio (IBIO)?
The latest analyst rating for iBio (AMEX: IBIO) was provided by JMP Securities, and iBio downgraded their market perform rating.
When is the next analyst rating going to be posted or updated for iBio (IBIO)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of iBio, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for iBio was filed on February 16, 2023 so you should expect the next rating to be made available sometime around February 16, 2024.
Is the Analyst Rating iBio (IBIO) correct?
While ratings are subjective and will change, the latest iBio (IBIO) rating was a downgraded with a price target of $0.00 to $0.00. The current price iBio (IBIO) is trading at is $0.87, which is out of the analyst's predicted range.